Trial Profile
Phase I/II, open-label, dose escalating study of injectable RT 002 [botulinum toxin A] in patients with moderate to severe glabellar lines
Status:
Completed
Phase of Trial:
Phase I/II
Latest Information Update: 07 May 2015
Price :
$35
*
At a glance
- Drugs Daxibotulinumtoxin A (Primary)
- Indications Glabellar lines
- Focus Adverse reactions; Therapeutic Use
- 26 May 2014 New trial record
- 13 May 2014 Positive results from this study were reported in late April 2014, according to a Revance Therapeutics media release.
- 21 Apr 2014 Results published in the Media Release.